サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405788

中央検査室の市場規模、シェア、動向分析レポート：サービス別、最終用途別、地域別、セグメント予測、2024年～2030年

Central Lab Market Size, Share & Trends Analysis Report By Service (Genetic Services, Biomarker Services), By End-use (Pharmaceutical Companies, Biotechnology Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
中央検査室の市場規模、シェア、動向分析レポート：サービス別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月05日
発行: Grand View Research
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中央検査室市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の中央検査室市場規模は2024年から2030年にかけてCAGR 6.44％で拡大し、2030年には50億5,000万米ドルに達すると予測されています。

研究開発への投資が増加し、スポンサーや治験責任医師が研究コストの削減に重点を置くようになったことが背景にあり、予測期間中のCAGRは6.50%と予測されます。中央検査室業務のアウトソーシングは、市場成長を促進する重要な要因です。

中央検査室業務のアウトソーシングは臨床試験業界において増加傾向にあり、中央検査室にとって有利なビジネスチャンスが生まれると期待されています。治験責任医師やスポンサーは中央検査室業務の約80％を外注しており、エンドツーエンドの統合サービスを提供するラボを好んでいます。

研究開発への投資はここ数年急増しているが、これはパンデミック（世界的大流行）時に製薬業界への注目が高まったためです。パンデミックの3年目に入り、科学への投資はパイプラインを強化し、いくつかの臨床試験が開始されました。パンデミック期間中、インターベンショナル・スタディの活動は着実に拡大しました。製薬業界は、パンデミック中に進行中の臨床試験を管理するための新しい試験実施方法を開発しました。

パンデミックはまた、mRNAワクチンの開発やいくつかのCOVID-19治療法の検討への注目が高まるなど、新たな成長機会も生み出しました。しかし、臨床ラボに送られるサンプルには、サンプルの取り扱い、サプライチェーン、ロジスティクスが重要な役割を果たしています。これらのサンプルは高感度であり、温度管理を伴う迅速なロジスティクスを必要とし、それにより最も正確な結果を得るためにサンプルの安定性を維持する必要があります。

中小規模の中央検査機関の台頭は、世界の競合を激化させています。中小規模の中央検査室の存在は、アジア太平洋などの発展途上地域で非常に顕著です。さらに、新興経済諸国では臨床試験の実施コストが低いため、これらの地域に存在する中央検査機関の選択が容易になっています。これは、物流コストが低く、臨床試験実施場所の近くに存在するためです。

中央検査室市場レポートハイライト

  • 遺伝子サービス分野は、臨床研究における遺伝子解析の重要性の高まりにより、最も速い成長率で成長すると予測されます。
  • 戦略的買収は市場力学の変化に影響を与える要因の一つです。例えば、世界展開の強化や新規事業分野への参入を目的として、中堅・大企業が買収を行う。
  • 製薬会社が最終用途別で最大の市場シェアを占めているが、これは介入研究の増加や研究への投資に起因しています。
  • 2023年の世界市場は北米が支配的であったが、これは糖尿病やがんなどの疾患領域における個別化ヘルスケアに関連した臨床試験における遺伝子検査のニーズが高まっているためです。
  • 同市場の主要企業は、ACM Global Laboratories、Labconnect、Cerba Research、Eurofins Scientific、Medicover Integrated Clinical Services、Versitiなどです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因
    • 臨床試験への研究開発投資の増加
    • 新薬への需要の高まり
    • 中央検査業務のアウトソーシング
    • 医薬品調査のコストを削減する
  • 市場抑制要因分析
    • 物流とサンプルの取り扱い
  • 事業環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • COVID-19感染症の影響分析

第4章 サービス事業分析

  • 中央検査室市場：サービス変動分析
  • 遺伝サービス
  • バイオマーカーサービス
  • 微生物学サービス
  • 解剖病理学/組織学
  • 検体の管理と保管
  • 特殊化学サービス
  • その他

第5章 最終用途ビジネス分析

  • 中央検査室市場：最終用途の変動分析
  • 製薬会社
  • バイオテクノロジー企業
  • 学術研究機関

第6章 地域ビジネス分析

  • 地域別中央検査室市場シェア、2023年および2030年
  • 北米
    • 北米中央検査室市場、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州中央検査室市場、2018～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋地域の中央検査室市場、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカ中央検査室市場、2018～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA中央検査室市場、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • 中央検査室市場シェア分析、2023年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 3 Global Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 4 Global Central Lab Market, by Region, 2018 - 2030 (USD Million)
  • Table 5 North America Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 7 North America Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 8 U.S. Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 9 U.S. Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 Canada Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 11 Canada Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 12 Europe Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 14 Europe Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 15 Germany Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 16 Germany Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 17 UK Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 18 UK Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 France Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 20 France Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 21 Italy Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 22 Italy Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Spain Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 24 Spain Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Denmark Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 26 Denmark Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 27 Sweden Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 28 Sweden Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Norway Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 30 Norway Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 34 China Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 35 China Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 Japan Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 37 Japan Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 India Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 39 India Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 40 South Korea Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 41 South Korea Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Australia Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 43 Australia Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Thailand Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 45 Thailand Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 46 Latin America Central Lab Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 48 Latin America Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Brazil Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 50 Brazil Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Mexico Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 52 Mexico Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Argentina Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 54 Argentina Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 58 South Africa Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 59 South Africa Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 62 UAE Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 63 UAE Central Lab Market, by End Use, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Central Lab Market, by Service, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Central Lab Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Central Lab Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Central Lab Market: Service Movement Analysis
  • Fig. 15 Global Central Lab Market, by Genetic Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Central Lab Market, by Biomarker Services, 2018 - 2030 (USD Million)
  • Fig. 17 Global Central Lab Market, by Anatomic Pathology/Histology, 2018 - 2030 (USD Million)
  • Fig. 18 Global Central Lab Market, by Specimen Management & Storage, 2018 - 2030 (USD Million)
  • Fig. 19 Global Central Lab Market, by Special Chemistry Services, 2018 - 2030 (USD Million)
  • Fig. 20 Global Central Lab Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Central Lab Market: End-Use Movement Analysis
  • Fig. 22 Global Central Lab Market, by Pharmaceutical Companies 2018 - 2030 (USD Million)
  • Fig. 23 Global Central Lab Market, by Biotechnology Companies 2018 - 2030 (USD Million)
  • Fig. 24 Global Central Lab Market, by Academic & Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Outlook, 2023 & 2030
  • Fig. 27 Global Central Lab Market: Region Movement Analysis
  • Fig. 28 North America Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 33 UK Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 34 France Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 42 China Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 43 India Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE Central Lab Market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait Central Lab Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-962-2

Central Lab Market Growth & Trends:

The global central lab market size is expected to reach USD 5.05 billion by 2030, expanding at a CAGR of 6.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 6.50% during the forecast period, driven by the increasing investment in R&D and increased focus of sponsors & investigators on reducing research costs. The outsourcing of central lab work is a significant factor driving the market growth.

Outsourcing central lab work is a rising trend in the clinical trial industry, which is expected to create lucrative business opportunities for central labs. The investigators and sponsors outsource ~80% of the central lab work and prefer the labs that provide end-to-end integrated services.

Investment in R&D has witnessed a surge in past years, which can be attributed to the enhanced focus on the pharmaceutical industry during the pandemic. As we enter the third year of the pandemic, investment in science has enhanced the pipeline and several clinical trials have been initiated. Over the pandemic, activity in interventional studies grew steadily. The pharmaceutical industry developed a new way of conducting trials for the management of ongoing clinical trials during the pandemic.

The pandemic has also created new growth opportunities, with an increasing focus on mRNA vaccine development and investigations for several COVID-19 treatment options. However, sample handling, supply chain, and logistics play a significant role in the sample sent to clinical labs. These samples are highly sensitive and require fast logistics with temperature control, thereby maintaining sample stability to get the most accurate results.

The rise of small- and medium-scale central laboratories is intensifying the competition globally. The presence of small- and medium-scale central labs is highly prominent in developing regions such as the Asia Pacific. These laboratories are becoming critical in the management of clinical trials globally owing to the availability of central laboratory services at 20%-35% lower prices, when compared to Europe and the U.S. Furthermore, the lower cost of conducting clinical trials in the developing economies facilitates the selection of central laboratories present in these regions, which can be attributed to lower logistic costs and presence near the trial location.

Central Lab Market Report Highlights:

  • The genetic services segment is anticipated to grow at the fastest growth rate, owing to the increasing significance of genetic analysis in clinical studies
  • Strategic acquisitions are one of the factors influencing the changing dynamics of the market. For instance, players are acquired by medium and large-scale enterprises for enhancing their global reach and entering new business segments
  • Pharmaceutical companies held the largest market share by end-use, attributable to an increasing number of interventional studies and investment into research
  • North America dominated the global market in 2023, the increasing need for genetic testing in clinical trials related to personalized healthcare in disease areas, such as diabetes & cancers
  • Key players in the market include ACM Global Laboratories, Labconnect, Cerba Research, Eurofins Scientific, Medicover Integrated Clinical Services, and Versiti

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising R&D investment in clinical trial
    • 3.4.2. Escalating demand for novel drugs
    • 3.4.3. Outsourcing of central lab work
    • 3.4.4. Reducing the cost of drug research
  • 3.5. Market Restraint Analysis
    • 3.5.1. Logistics and sample handling
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Service Business Analysis

  • 4.1. Central Lab Market: Service Movement Analysis
  • 4.2. Genetic Services
    • 4.2.1. Genetic Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.3. Biomarker Services
    • 4.3.1. Biomarker Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.4. Microbiology Services
    • 4.4.1. Microbiology Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.5. Anatomic Pathology/Histology
    • 4.5.1. Anatomic Pathology/Histology Central Lab Market, 2018 - 2030 (USD Million)
  • 4.6. Specimen Management and Storage
    • 4.6.1. Specimen Management and Storage Central Lab Market, 2018 - 2030 (USD Million)
  • 4.7. Special Chemistry Services
    • 4.7.1. Special Chemistry Services Central Lab Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Central Lab Market, 2018 - 2030 (USD Million)

Chapter 5. End Use Business Analysis

  • 5.1. Central Lab Market: End-Use Movement Analysis
  • 5.2. Pharmaceutical Companies
    • 5.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 5.3. Biotechnology Companies
    • 5.3.1. Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 5.4. Academic and Research Institutes
    • 5.4.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Central Lab Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. North America Central lab market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target Disease Prevalence
      • 6.2.2.3. Competitive Scenario
      • 6.2.2.4. Regulatory Framework
      • 6.2.2.5. Reimbursement Scenario
      • 6.2.2.6. U.S. Central lab market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Reimbursement Scenario
      • 6.2.3.6. Canada Central lab market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Central lab market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. Competitive Scenario
      • 6.3.2.4. Regulatory Framework
      • 6.3.2.5. Reimbursement Scenario
      • 6.3.2.6. Germany Central lab market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Reimbursement Scenario
      • 6.3.3.6. UK Central lab market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Reimbursement Scenario
      • 6.3.4.6. France Central lab market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Reimbursement Scenario
      • 6.3.5.6. Italy Central lab market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Reimbursement Scenario
      • 6.3.6.6. Spain Central lab market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Reimbursement Scenario
      • 6.3.7.6. Denmark Central lab market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Reimbursement Scenario
      • 6.3.8.6. Sweden Central lab market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Reimbursement Scenario
      • 6.3.9.6. Norway Central lab market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Central lab market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Regulatory Framework
      • 6.4.2.5. Reimbursement Scenario
      • 6.4.2.6. Japan Central lab market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Reimbursement Scenario
      • 6.4.3.6. China Central lab market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Reimbursement Scenario
      • 6.4.4.6. India Central lab market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. Reimbursement Scenario
      • 6.4.5.6. South Korea Central lab market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Reimbursement Scenario
      • 6.4.6.6. Australia Central lab market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Reimbursement Scenario
      • 6.4.7.6. Thailand Central lab market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Central lab market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Regulatory Framework
      • 6.5.2.5. Reimbursement Scenario
      • 6.5.2.6. Brazil Central lab market, 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Reimbursement Scenario
      • 6.5.3.6. Mexico Central lab market, 2018 - 2030 (USD Million)
    • 6.5.4. Argentina
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Reimbursement Scenario
      • 6.5.4.6. Argentina Central lab market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Central lab market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. Regulatory Framework
      • 6.6.2.5. Reimbursement Scenario
      • 6.6.2.6. South Africa Central lab market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. Reimbursement Scenario
      • 6.6.3.6. Saudi Arabia Central lab market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Reimbursement Scenario
      • 6.6.4.6. UAE Central lab market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. Reimbursement Scenario
      • 6.6.5.6. Kuwait Central lab market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant's overview
  • 7.2. Financial performance
  • 7.3. Participant categorization
    • 7.3.1. Market Leaders
    • 7.3.2. Central Lab Market Share Analysis, 2023
    • 7.3.3. Company Profiles
      • 7.3.3.1. ACM Global Laboratories
      • 7.3.3.1.1. Company Overview
      • 7.3.3.1.2. Financial Performance
      • 7.3.3.1.3. Product Benchmarking
      • 7.3.3.1.4. Strategic Initiatives
      • 7.3.3.2. LabConnect
      • 7.3.3.2.1. Company Overview
      • 7.3.3.2.2. Financial Performance
      • 7.3.3.2.3. Product Benchmarking
      • 7.3.3.2.4. Strategic Initiatives
      • 7.3.3.3. Cerba Research
      • 7.3.3.3.1. Company Overview
      • 7.3.3.3.2. Financial Performance
      • 7.3.3.3.3. Product Benchmarking
      • 7.3.3.3.4. Strategic Initiatives
      • 7.3.3.4. Eurofins Scientific
      • 7.3.3.4.1. Company Overview
      • 7.3.3.4.2. Financial Performance
      • 7.3.3.4.3. Product Benchmarking
      • 7.3.3.4.4. Strategic Initiatives
      • 7.3.3.5. Versiti (Cenetron)
      • 7.3.3.5.1. Company Overview
      • 7.3.3.5.2. Financial Performance
      • 7.3.3.5.3. Product Benchmarking
      • 7.3.3.5.4. Strategic Initiatives
      • 7.3.3.6. Medicover Integrated Clinical Services (MICS) (Synevo Central Labs)
      • 7.3.3.6.1. Company Overview
      • 7.3.3.6.2. Financial Performance
      • 7.3.3.6.3. Product Benchmarking
      • 7.3.3.6.4. Strategic Initiatives
      • 7.3.3.7. A.P. Møller Holding A/S (Unilabs)
      • 7.3.3.7.1. Company Overview
      • 7.3.3.7.2. Financial Performance
      • 7.3.3.7.3. Product Benchmarking
      • 7.3.3.7.4. Strategic Initiatives
      • 7.3.3.8. Ampersand Capital Partners (Pacific Biomarkers)
      • 7.3.3.8.1. Company Overview
      • 7.3.3.8.2. Financial Performance
      • 7.3.3.8.3. Product Benchmarking
      • 7.3.3.8.4. Strategic Initiatives
      • 7.3.3.9. Lambda Therapeutic Research Ltd
      • 7.3.3.9.1. Company Overview
      • 7.3.3.9.2. Financial Performance
      • 7.3.3.9.3. Product Benchmarking
      • 7.3.3.9.4. Strategic Initiatives
      • 7.3.3.10. CIRION BioPharma Research Inc.
      • 7.3.3.10.1. Company Overview
      • 7.3.3.10.2. Financial Performance
      • 7.3.3.10.3. Product Benchmarking
      • 7.3.3.10.4. Strategic Initiatives
    • 7.3.4. Strategy Mapping
      • 7.3.4.1. Expansion
      • 7.3.4.2. Acquisition
      • 7.3.4.3. Collaborations
      • 7.3.4.4. Disease Type/Drug Class Launch
      • 7.3.4.5. Partnerships
      • 7.3.4.6. Others